domingo, 20 de noviembre de 2016
More Immunotherapy Options Approved for Lung Cancer
FDA Adds Immunotherapy Approvals for Lung Cancer - National Cancer Institute
The Food and Drug Administration (FDA) has approved a new immunotherapy drug for some patients with non-small cell lung cancer (NSCLC) and expanded the approval of another immunotherapy drug for NSCLC so that it is now available for more patients. On October 18, the agency approved atezolizumab (Tecentriq®) for the treatment of metastatic NSCLC that has progressed during or after first-line chemotherapy with a platinum-based drug.